Browse the evidence

Unilateral immobilization or unloading causes profound muscle atrophy and metabolic risk factors in the immobilized limb, but these adaptations are specific to that limb and do not transfer to the non-immobilized control limb.

If you have to immobilize one limb (e.g., in a cast), expect that specific limb to lose muscle mass and strength, but know that your other limb will remain healthy and strong. This local specificity means you can maintain overall body function and use the healthy limb to support yourself without risking systemic decline.

Treatment with GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) is associated with a significantly increased risk of developing psychiatric disorders, including major depression, anxiety, and suicidal behavior, in patients with obesity.

If you are taking or considering GLP-1 medications like Ozempic or Wegovy for obesity, be aware that studies link these drugs to a higher risk of depression, anxiety, and suicidal thoughts, especially with long-term use. Discuss your mental health history with your doctor before starting, and monitor your mood closely. If you experience worsening depression or suicidal thoughts, contact your healthcare provider immediately.

Adding a Very Low-Calorie Diet (VLCD) to a Weight-Management Programme (WMP) is not cost-effective compared to a WMP alone, despite producing greater short-term weight loss.

For those with severe obesity, adding a Very Low-Calorie Diet to a standard weight management program provides more weight loss in the first year but is not considered cost-effective. Standard WMPs are a more economically sound approach.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with increased subclinical atherosclerosis (measured by carotid intima-media thickness and coronary artery calcification) and incident cardiovascular events, but does not independently increase cardiovascular mortality risk after adjusting for confounders.

If you have MASLD, prioritize cardiovascular risk management (blood pressure, lipids, glucose) as aggressively as you manage your liver health. Your risk of heart events is elevated, but your risk of dying from liver failure is lower than dying from heart disease. Comprehensive cardiometabolic risk management is warranted.

Enhanced Negative Work-based Training (ENT) does not significantly improve linear sprinting ability (10m and 30m) in semi-professional soccer players during the in-season period.

Do not rely on a single weekly flywheel session to improve your straight-line speed during the season. While it helps with change of direction and injury prevention, it does not significantly impact 10m or 30m sprint times in semi-professional players. Focus on specific speed training for linear sprinting.

In individuals with incident type 2 diabetes, higher pre-diagnosis BMI is positively associated with an increased risk of microvascular complications (kidney disease and neuropathy), but not macrovascular complications.

For someone with newly diagnosed Type 2 Diabetes, maintaining a healthy pre-diagnosis BMI is crucial for preventing kidney and nerve damage. While weight loss after diagnosis shows benefits, the baseline weight status before diagnosis significantly impacts long-term microvascular risk. Focus on preventing weight gain and managing metabolic health markers.

GLP-1 receptor agonists do not significantly increase energy expenditure in humans, despite evidence in animal models.

Don't expect GLP-1 drugs to burn extra calories at rest. They work by reducing food intake.

L-cells are not a homogeneous population; they are anatomically heterogeneous, with proximal (duodenal/jejunal) L-cells primarily secreting GLP-1 in response to macronutrients, while distal (ileal/colonic) L-cells co-secrete PYY and respond to microbial metabolites like SCFAs and bile acids.

Your gut's hormonal response to food depends on where the food is absorbed. Eating fiber and fats that reach the lower intestine (via fermentation or specific fats) stimulates different hormones (like PYY) than eating simple sugars in the upper intestine. A diverse diet that reaches different parts of the gut may optimize this hormonal signaling better than focusing on a single nutrient type.

Higher circulating concentrations of fatty acids produced via de novo lipogenesis (specifically 16:0, 16:1n7, and 18:0) are positively associated with an increased incidence of type 2 diabetes.

High levels of certain fats produced by your body (de novo lipogenesis) from carbs and alcohol are linked to a higher risk of type 2 diabetes. This suggests that managing carbohydrate and alcohol intake may help regulate these specific internal fat pathways, potentially lowering diabetes risk, independent of overall body weight.

The association between oleic acid (18:1n9) and type 2 diabetes risk is attenuated to non-significance when adjusted for triglycerides and palmitic acid (16:0), suggesting its risk is dependent on overall de novo lipogenesis activity rather than being an independent driver.

While high levels of some fats made by your body are linked to diabetes, the link for oleic acid (found in olive oil) disappears when you account for overall metabolic health markers like triglycerides. This implies that focusing on the broader metabolic context (carb/alcohol intake) is more important than demonizing specific fats like oleic acid.

Deletion or inhibition of MKK6 in white adipose tissue increases energy expenditure and protects against diet-induced obesity and diabetes by enhancing thyroid hormone (T3)-mediated browning of white fat.

This research suggests that blocking MKK6 in fat tissue could help treat obesity by making fat burn more energy, similar to brown fat. While not a current human treatment, it highlights thyroid hormone sensitivity and fat metabolism as key targets for future obesity drugs.

Enteroendocrine cells (EECs) regulate the gut-brain axis through two distinct mechanisms: slow endocrine hormone release into the bloodstream and rapid synaptic signaling via neuropod cells.

Your gut has a direct 'phone line' to your brain. Foods trigger specific cells (EECs) that send signals either slowly through hormones or instantly through nerves. This is why drugs like semaglutide (Ozempic) work—they amplify these natural signals to regulate hunger and blood sugar. Understanding this helps explain why gut health directly impacts mood and metabolism.

Neuropod cells communicate nutrient information to the vagus nerve primarily via glutamate release, allowing for rapid distinction between sugar and artificial sweeteners.

Your gut has a specific 'sugar detector' (neuropod cells) that sends a fast signal to your brain using glutamate. This signal is triggered by real sugar (sucrose) but not by artificial sweeteners. This might explain why artificial sweeteners don't always satisfy sugar cravings or trigger the same metabolic responses as real sugar.

Serotonin (5-HT) released from enterochromaffin (EC) cells modulates visceral sensitivity and pain signaling via direct synaptic interaction with nociceptive neurons.

If you have IBS or chronic gut pain, your gut cells (EC cells) might be sending too many pain signals to your brain using serotonin. Blocking these signals (with specific antagonists) can reduce pain and anxiety, showing that gut pain is a neurological issue, not just inflammation.

The EAT-Lancet diet score without minimum intake values for nutrient-dense food groups negatively predicts micronutrient adequacy in rural women of reproductive age in low- and middle-income countries, whereas adding minimum intake values (>0 g/d) reverses this association to a positive one.

When evaluating diet quality in low-resource settings, do not use scoring systems that allow zero consumption of nutrient-dense foods (like meat, dairy, or legumes) to earn points. These scores will falsely label malnourished diets as 'healthy.' Always apply minimum intake thresholds to ensure the score reflects actual nutrient adequacy.

Short-term resistance exercise (3 bouts over 9 days) combined with a high-fat diet does not prevent the high-fat diet-induced upregulation of immune and inflammatory genes in skeletal muscle, although it does remodel genes associated with muscle growth and structure.

If you are eating a high-fat, low-carb diet, doing resistance exercise for just a few days will not stop your muscles from turning on inflammatory genes. While exercise does build muscle structure genes, it doesn't stop the inflammation caused by the diet. You likely need longer-term training to see protective effects, but don't assume a few workouts cancel out the dietary stress.

Short-term high-fat diet induces DNA hypermethylation and alters gene expression of PYGM (glycogen phosphorylase, muscle), an adaptive epigenetic response to glycogen depletion, which is preserved by resistance exercise.

When you switch to a low-carb/high-fat diet, your body epigenetically silences the gene responsible for breaking down glycogen (PYGM) because you aren't eating carbs. This is a smart adaptation. Exercise helps maintain this state but doesn't change this specific epigenetic switch.

No country globally achieves the combined WHO target of potassium intake >3.5 g/day and sodium intake <2 g/day.

It is currently impossible to meet both sodium and potassium guidelines simultaneously in most countries. Focus on reducing discretionary salt intake and increasing potassium-rich foods like fruits and vegetables, as this is the most feasible path to improving cardiovascular health.

Tirzepatide treatment is not significantly associated with an increased risk of pancreatitis compared to control groups (placebo, basal insulin, or GLP-1 RAs) in patients with type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity and are considering Tirzepatide, current data from multiple clinical trials suggests it does not significantly increase your risk of pancreatitis compared to other common diabetes or weight-loss medications. This is reassuring news if you were avoiding the drug due to fears of pancreatic inflammation.

Tirzepatide is associated with a significantly increased risk of composite gallbladder or biliary diseases (including cholelithiasis, cholecystitis, and other gallbladder disorders) compared to placebo or basal insulin, but not compared to GLP-1 RAs.

Tirzepatide increases the risk of gallbladder or biliary issues (like gallstones or inflammation) compared to placebos or insulin. However, this risk appears similar to other GLP-1 medications. Be aware of symptoms like abdominal pain and report them to your doctor promptly, as early detection is key.

In patients with new-onset type 2 diabetes, a weight loss of 10% or more within the first two years is associated with the highest risk of all-cause mortality.

If you have recently been diagnosed with type 2 diabetes, avoid losing more than 10% of your body weight in the first two years. Significant weight loss in this context is linked to higher mortality, possibly due to muscle loss or other health issues. Focus on maintaining a stable weight rather than aggressive weight loss.

Food industry sponsorship of academic research systematically biases the research agenda toward physical activity and nutrient-specific interventions, thereby diverting attention from the health impacts of highly processed foods and ultra-processed diets.

When evaluating health advice or research, always check the funding source. If a study on obesity or nutrition is funded by a food or beverage company, be skeptical of conclusions that emphasize exercise or specific nutrients while ignoring the role of highly processed foods. Prioritize research that is independent of industry funding or focuses on whole dietary patterns rather than isolated components.

Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.

AMPK activation inhibits ribosome biogenesis by blocking mTORC1 signaling, while mTORC1 signaling may negatively affect mitochondrial biogenesis, creating a molecular competition.

This is a molecular detail. For training, it means high-energy demand (endurance) signals the body to build mitochondria, potentially suppressing the signal to build protein (muscle) if not managed.